Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.56 |
| ▸ | LIPE | Q05469 | 1/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951108 | 0.93 | GPR119 (0.63) | GPR119LIPEUSP30CHEK2EPHX2 | |
| SCHEMBL29981348 | 0.88 | GPR119 (0.58) | GPR119LIPECHEK2EPHX2ALDH1A1 | |
| SCHEMBL23410126 | 0.88 | GPR119 (0.58) | GPR119LIPECHEK2EPHX2ALDH1A1 | |
| SCHEMBL23632967 | 0.88 | USP30 (0.57) | GPR119LIPEUSP30PIK3CDCHEK2 | |
| SCHEMBL3077366 | 0.88 | USP30 (0.57) | GPR119LIPEUSP30PIK3CDCHEK2 | |
| SCHEMBL23632146 | 0.88 | USP30 (0.57) | GPR119LIPEUSP30PIK3CDCHEK2 | |
| SCHEMBL3377761 | 0.88 | GPR119 (0.57) | GPR119USP30PIK3CDCHEK2ALDH1A1 | |
| SCHEMBL19838626 | 0.88 | GPR119 (0.57) | GPR119USP30PIK3CDCHEK2ALDH1A1 | |
| SCHEMBL6189661 | 0.86 | GPR119 (0.58) | GPR119USP30PIK3CDCHEK2ALDH1A1 | |
| SCHEMBL20179924 | 0.86 | GPR119 (0.58) | GPR119USP30PIK3CDCHEK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | GPR119 1331/4885LIPE 4493/4885USP30 3717/4885 |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | GPR119 926/4885LIPE 903/4885USP30 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.